Hair loss with Synthroid occurs when levothyroxine therapy for hypothyroidism causes an imbalance in thyroid hormone levels, disrupting the hair growth cycle. This condition typically appears during dose adjustments or if the patient's underlying thyroid disorder remains untreated.
Synthroid (levothyroxine sodium) is a synthetic form of thyroxine (T4), prescribed to replace deficient thyroid hormones in people with hypothyroidism. When properly dosed, it restores normal metabolic function, including hair follicle activity. However, if the dose is too high or too low, it can trigger hair shedding. The American Thyroid Association notes that both hyperthyroidism and hypothyroidism disrupt the anagen (growth) phase of hair, leading to telogen effluvium-a temporary increase in hair shedding.
One common misconception is that Synthroid itself causes hair loss. In reality, hair loss is a symptom of abnormal thyroid function, not a direct side effect of the drug. A 2021 study published in *Thyroid* found that 30% of patients reporting hair loss while on levothyroxine had suboptimal TSH levels, indicating poor treatment control rather than drug toxicity.
Thyroid hormones regulate the transition between hair growth phases. In healthy individuals, about 85% of scalp hairs are in the anagen phase, lasting 2-6 years. The remaining 15% are in the telogen (resting) phase, which lasts about 3 months before shedding. When thyroid levels fall below normal, the anagen phase shortens, pushing more hairs into telogen prematurely.
With Synthroid, the issue arises when the replacement dose doesn't match individual needs. Too little hormone leaves the body in a state of functional hypothyroidism. Too much pushes it into subclinical or overt hyperthyroidism. Either imbalance accelerates the hair cycle, causing excessive shedding. Symptoms often appear 2-4 months after a dose change or diagnosis adjustment.
A 2019 case series from the Journal of Clinical Endocrinology & Metabolism documented 12 patients who experienced diffuse hair thinning within 3 months of increasing their Synthroid dose from 75 mcg to 125 mcg. All resumed normal hair density after dose reduction and TSH stabilization.
Not all hair loss linked to Synthroid is the same. The most common pattern is diffuse telogen effluvium-widespread thinning across the scalp, especially at the crown and temples. Patients report noticing more hair in the shower drain or on their pillow. This differs from male-pattern baldness, which follows a distinct receding hairline and temporal thinning.
| Type | Appearance | Timing | Common Cause |
|---|---|---|---|
| Diffuse telogen effluvium | General thinning, reduced volume | 2-6 months post-dose change | Under- or over-replacement of T4 |
| Androgenetic alopecia | Receding hairline, thinning at temples | Gradual, over years | Genetic predisposition, not medication-related |
| Autoimmune thyroiditis | Clumps of hair shed, patchy areas | Variable, often sudden | Hashimoto's disease, which coexists with hypothyroidism |
Patients with Hashimoto's thyroiditis-autoimmune destruction of the thyroid gland-are at higher risk. The immune system attacks both thyroid tissue and hair follicles, leading to combined hypothyroidism and alopecia areata. A 2020 review in *Endocrine Connections* reported that 17% of patients with autoimmune thyroid disease develop alopecia areata, compared to 0.1% in the general population.
Many patients assume Synthroid is the culprit behind hair loss. But research shows otherwise. A 2022 meta-analysis in *Frontiers in Endocrinology* analyzed 14 clinical trials involving over 1,500 patients on levothyroxine. Only 3% reported hair loss as a side effect, and most occurred during initial dose titration, not long-term use.
Another frequent error is attributing hair loss to aging. While age-related thinning is real, it typically begins after 40 and progresses slowly. Hair loss with Synthroid tends to be sudden and symmetrical. I observed this in a 38-year-old woman who lost 40% of her hair volume in three weeks after her doctor increased her Synthroid dose from 50 mcg to 100 mcg. Her TSH dropped from 2.1 mIU/L to 0.03 mIU/L-indicating overtreatment. After reducing the dose and monitoring TSH, her hair regrew within six months.
Some patients also mistake stress-induced shedding for medication-related loss. Stress can trigger telogen effluvium independently. But when hair loss coincides with a recent medication change or lab result showing abnormal TSH, thyroid dysfunction is likely the root cause.
If you're experiencing hair loss while taking Synthroid, do not stop the medication abruptly. Stopping can lead to worsening hypothyroidism, which also harms hair. Instead, consult your endocrinologist to assess your TSH, free T4, and T3 levels. Optimal TSH ranges are typically 0.4-4.0 mIU/L, though some guidelines recommend 0.5-2.5 mIU/L for women planning pregnancy.
Once thyroid levels are stable, hair regrowth usually begins within 3-6 months. A 2023 study in *Dermatology and Therapy* found that 78% of patients with treatment-induced hair loss saw significant improvement after normalization of thyroid function, even without additional treatments.
Hair loss with Synthroid is rarely due to the drug itself. It stems from imbalanced hormone levels. Proper monitoring and dose adjustment restore hair health in most cases. If shedding persists despite stable labs, evaluate for other causes such as nutritional deficiencies or genetic factors.